Scholarlink

<p>This retrospective study evaluates the efficacy, safety, and steroid-sparing effect of tofacitinib combined with corticosteroids (CS) in treating pemphigus. We analyzed clinical data from moderate pemphigus patients treated with CS monotherapy or CS plus tofacitinib (CT) between June 2019 and January 2024. The primary endpoint was the complete remission (CR) rate at 1 year following the initiation of respective therapies. Secondary endpoints comprised the monthly number of patients achieving the minimum therapeutic dose of corticosteroids (CSmin) therapy, total annual cumulative CS doses, monthly median CS doses, relapse frequency within 1 year post-treatment initiation, and adverse events (AEs). Transcriptomic profiling (RNA-sequencing), Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence (IF) were performed to assess JAK-STAT pathway activation. Twelve patients were enrolled in the CS group and 10 in the CT group. No significant difference in CR rates was observed (16.67% vs. 40.00%, <i>P</i> = 0.35), but the CT group demonstrated a 4.46-fold higher probability of achieving CR (HR = 4.46, <i>P</i> = 0.04). The CT group has more patients achieved CSmin, with lower cumulative (6,862.25 vs. 10,233&#xa0;mg, <i>P</i> &lt; 0.001) and median monthly CS doses. AEs incidence (70% vs. 41.67%, <i>P</i> = 0.35) and relapse rates (60% vs. 16.67%, <i>P</i> = 0.07) did not differ significantly. Transcriptomic and IF analyses confirmed JAK-STAT pathway hyperactivation in pemphigus lesions. Tofacitinib adjunct therapy demonstrated significant steroid-sparing benefits with comparable efficacy and safety to CS monotherapy in pemphigus, supported by mechanistic evidence of JAK-STAT pathway hyperactivation in pemphigus.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world evaluation of the efficacy and safety of Tofacitinib combined with corticosteroids in the treatment of pemphigus: a single-center cohort study

  • 期刊论文

  • 发表日期：

    2025年7月16日

查看全文
  • Xiang Li,
  • Juan Zhang,
  • Lu Sun,
  • Ling Li,
  • Huan Wang,
  • Juan Wang,
  • Chunyou Wang,
  • Lian Zhang,
  • Hongzhi Gu,
  • Wanzhen He,
  • Huirong Cao,
  • Xuemei Wen,
  • Zhifang Zhai,
  • Mingwang Zhang

摘要

This retrospective study evaluates the efficacy, safety, and steroid-sparing effect of tofacitinib combined with corticosteroids (CS) in treating pemphigus. We analyzed clinical data from moderate pemphigus patients treated with CS monotherapy or CS plus tofacitinib (CT) between June 2019 and January 2024. The primary endpoint was the complete remission (CR) rate at 1 year following the initiation of respective therapies. Secondary endpoints comprised the monthly number of patients achieving the minimum therapeutic dose of corticosteroids (CSmin) therapy, total annual cumulative CS doses, monthly median CS doses, relapse frequency within 1 year post-treatment initiation, and adverse events (AEs). Transcriptomic profiling (RNA-sequencing), Reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence (IF) were performed to assess JAK-STAT pathway activation. Twelve patients were enrolled in the CS group and 10 in the CT group. No significant difference in CR rates was observed (16.67% vs. 40.00%, P = 0.35), but the CT group demonstrated a 4.46-fold higher probability of achieving CR (HR = 4.46, P = 0.04). The CT group has more patients achieved CSmin, with lower cumulative (6,862.25 vs. 10,233 mg, P < 0.001) and median monthly CS doses. AEs incidence (70% vs. 41.67%, P = 0.35) and relapse rates (60% vs. 16.67%, P = 0.07) did not differ significantly. Transcriptomic and IF analyses confirmed JAK-STAT pathway hyperactivation in pemphigus lesions. Tofacitinib adjunct therapy demonstrated significant steroid-sparing benefits with comparable efficacy and safety to CS monotherapy in pemphigus, supported by mechanistic evidence of JAK-STAT pathway hyperactivation in pemphigus.